68
Views
25
CrossRef citations to date
0
Altmetric
Original Article

Anti- CD16/CD30 Bispecific Antibodies as Possible Treatment for Refractory Hodgkin's Disease

, , &
Pages 385-392 | Published online: 01 Jul 2009

References

  • Devita V. T. The consequences of chemotherapy of Hodgkin's disease: the 10th David A. Karnofsky Memorial Lecture. Cancer 1987; 47: 1–13
  • Milstein C., Cuello A. C. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983; 305: 537–540
  • Renner C., Pfreundschuh M. Tumor therapy by immune recruitment with bispecific antibodies. Immunol. Rev. 1995; 145: 179–209
  • Hombach A., Jung W., Pohl C., Renner C., Sahin U., Schmits R., Wolf J., Kapp U., Diehl V., Pfreundschuh M. CD16/CD30 bispecific antibody induces lysis of Hodgkin cells by unstimulated natural killer cells in vitro and in vivo. Int. J. Cancer 1993; 55: 830–837
  • Pohl C., Denfeld R., Renner C., Jung W., Bohlen H., Sahin U., Hombach A., Van Lier R., Schwonzen M., Diehl V., Pfreundschuh M. CD30-antigen-specific targeting and activation of T-cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma. Int. J. Cancer 1993; 54: 820–827
  • Renner C., Jung W., Sahin U., Denfeld R., Pohl C., Trümper L., Hartmann F., Diehl V., Van Lier R., Pfreundschuh M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994; 264: 833–835
  • Falini B., Piled S., Pizzolo G., Diirkop H., Flenghi L., Stirpe E., Martelli M. E, Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1–14
  • Hartmann E., Renner C., Jung W., Deisting C., Juwana M., Eichentopf B., Kloft M., Pfreundschuh M. Treatment of refractory Hodgkin's disease with an anti-CD 16/CD30 bispecific antibody. Blood 1997; 89: 2042–2047
  • Investigator's handbook. A Manual for participants in clinical trials of investigational agents. Cancer therapy evaluation program. DCT, NCI, Bethesda, MD 1993, 20892, USA
  • Pohl C., Renner C., Schwonzen M., Sieber M., Lorenz P., Pfreundschuh M., Diehl V. Anti-idiotype vaccine against Hodgkin's lymphoma: induction of B- and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies. Int. J. Cancer 1992; 50: 958–967
  • Blomberg K., Ulfstedt A. C. Fluorescent europium chelates as target cell markers in the assessment of natural killer cell cytotoxicity. J. Immunol. Meth. 1993; 160: 27–38
  • Bolhuis R. L., Lamers C. H., Goey S. H., Eggermont A. M., Trimbos J. B., Stoter G., Lanzavecchia A., Di Re E., Miotti S., Raspagliesi E., Rivoltini L., Colnaghi M. I. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int. J. Cancer 1992; 78(Suppl 7)78–81
  • Canevari S., Stoter G., Arienti E., Bolis G., Colnaghi M. I., Di Re E. M., Eggermont A. M.M., Goey S. H., Gratama J. W., Lamers C. H.J., Nooy M. A., Parmiani G., Raspagliesi E., Ravagnani E., Scarfone G., Trimbos J. B., Warnaar S. O., Bolhuis R. L.H. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst. 1995; 87: 1463–1469
  • De Gast G. C., Haagen I. A., Van Houten A. A., Klein S. C., Duits A. J., De Weger R. A., Vroom T. M., Clark M. R., Phillips S., Van Dijk A. J., Bast B. J.H. CDS T cell activation after intravenous administration of CD3xCDl9 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol. Immunother. 1995; 40: 390–396
  • Kroesen B. J., Ter Haar A., Spakman H., Willemse P., Sleijfer D. T., De Vries E. G., Mulder N. H., Berendsen H. H., Limburg P C, The T. H., De Leij L. Local antitumour treatment in carcinoma patients with bispecific monoclonal antibody redirected T cells. Cancer Immunol. Immunother. 1993; 37: 400–407
  • Kroesen B. J., Buter J., Sleijfer D. T., Janssen R. A., Van Der Graaf W. T., The T. H., De Leij L., Mulder N. H. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br. J. Cancer 1994; 70: 652–661
  • Nitta T., Sato K., Yagita H., Okumura E., Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990; 335: 368–371
  • Tibben J. G., Boerman O. C., Massuger L. E, Schijf C. P., Claessens R. A., Corstens E H. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. Int. J. Cancer 1996; 66: 477–483
  • Valone F. H., Kaufman P. A., Guyre P. M., Lewis L. D., Memoli V., Deo Y., Graziano R., Fisher J. L., Meyer L., Mrozek-Orlowski M., Wardwell K., Guyre V., Morley T. L., Arvizu C., Fanger M. W. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene Her-2/neu.X. Clin. Oncol. 1995; 13: 2281–2292
  • Curnow R. T., Pfister D. G., Deo Y., Motzer R. J., Winston C., Keeperman K. L., Malone T. A phase I trial of bispecific antibody (BsAB) MDX447 without and with granulocyte colony-stimulating factor (G-CSF) in patients with adult solid tumors. Proc. Am. Soc. Clin. Oncol. 1997; 16: 1571, abstract
  • Weiner L. M., Clark J. I., Davey M., Li W. S., De Palazzo I. G., Ring D. B., Alpaugh R. K. Phase I Trial of 2B1, a bispecific monoclonal antibody targeting c-erB-2 and FCγRIII. Cancer Res. 1995; 55: 4586–4593
  • Clark J. I., Alpaugh R. K., Von Mehren M., Schultz J., Gralow J. R., Cheever M. A., Ring D. B., Weiner L. M. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol. Immunother. 1997; 44: 265–272
  • Lamers C. H.J., Gratama I. W., Warnaar S. O., Stoter G., Bolhuis R. L.H. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAB-targeted activated T-lymphocytes. Int. J. Cancer 1995; 60: 450–457
  • Hartmann R., Renner C., Tembrink S., Held G., Ames M., Jung W., Pfreundschuh M. Treatment of refractory Hodgkin's disease (HD) with an and- CD30/CD16 bispecific monoclonal antibody (BiMAb). Proc. Am. Soc. Clin. Oncol. 1998; 17: 60, abstract
  • Holliger P., Prospero T., Winter G. Diabodies: Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 1993; 90: 6444–6448
  • Mack M., Riethmüller G., Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. USA 1995; 92: 7021–7025

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.